These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1534 related items for PubMed ID: 21045814

  • 1. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
    D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S.
    Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
    [Abstract] [Full Text] [Related]

  • 2. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.
    Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF.
    Am J Gastroenterol; 2011 Feb; 106(2):214-23; quiz 224. PubMed ID: 21157441
    [Abstract] [Full Text] [Related]

  • 3. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A.
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [Abstract] [Full Text] [Related]

  • 4. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L.
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
    [Abstract] [Full Text] [Related]

  • 5. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
    Gisbert JP, Marín AC, McNicholl AG, Chaparro M.
    Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
    [Abstract] [Full Text] [Related]

  • 6. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
    D'Haens G.
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
    [Abstract] [Full Text] [Related]

  • 7. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW, Bickston SJ.
    Cochrane Database Syst Rev; 2008 Jan 23; (1):CD006893. PubMed ID: 18254120
    [Abstract] [Full Text] [Related]

  • 8. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun 23; 18(101):108-10. PubMed ID: 19637418
    [Abstract] [Full Text] [Related]

  • 9. Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails?
    Lakatos PL.
    Rev Recent Clin Trials; 2009 Sep 23; 4(3):152-8. PubMed ID: 20028325
    [Abstract] [Full Text] [Related]

  • 10. How to manage difficult Crohn's disease: optimum delivery of anti-TNFs.
    Krygier DS, Ko HH, Bressler B.
    Expert Rev Gastroenterol Hepatol; 2009 Aug 23; 3(4):407-15. PubMed ID: 19673627
    [Abstract] [Full Text] [Related]

  • 11. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECISE 2 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):239-50. PubMed ID: 17634459
    [Abstract] [Full Text] [Related]

  • 12. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
    Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ.
    Aliment Pharmacol Ther; 2010 Aug 19; 32(3):384-93. PubMed ID: 20491747
    [Abstract] [Full Text] [Related]

  • 13. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
    Smith LS, Nelson M, Dolder CR.
    Ann Pharmacother; 2010 Feb 19; 44(2):333-42. PubMed ID: 20118143
    [Abstract] [Full Text] [Related]

  • 14. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.
    Dig Liver Dis; 2005 Jun 19; 37(6):407-17. PubMed ID: 15893279
    [Abstract] [Full Text] [Related]

  • 15. Crohn's targeted therapy: myth or real goal?
    Schmidt KJ, Büning J, Jankowiak C, Lehnert H, Fellermann K.
    Curr Drug Discov Technol; 2009 Dec 19; 6(4):290-8. PubMed ID: 20025597
    [Abstract] [Full Text] [Related]

  • 16. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F, Portela F.
    BioDrugs; 2010 Dec 14; 24 Suppl 1():3-14. PubMed ID: 21175228
    [Abstract] [Full Text] [Related]

  • 17. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
    Lee TW, Fedorak RN.
    Gastroenterol Clin North Am; 2010 Sep 14; 39(3):543-57. PubMed ID: 20951917
    [Abstract] [Full Text] [Related]

  • 18. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
    Nobile S, Gionchetti P, Rizzello F, Calabrese C, Campieri M.
    Eur J Gastroenterol Hepatol; 2014 Apr 14; 26(4):458-65. PubMed ID: 24445727
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW, Lawrance IC.
    J Gastroenterol Hepatol; 2009 Jul 14; 24(7):1252-7. PubMed ID: 19220669
    [Abstract] [Full Text] [Related]

  • 20. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
    Leung Y, Hanauer SB.
    Gastroenterol Clin Biol; 2009 Jun 14; 33 Suppl 3():S202-8. PubMed ID: 20117343
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.